KURAに登録されているコンテンツの著作権は、執筆者、出版社（学会協）などが有します。
KURAに登録されているコンテンツの利用については、著作権法に規定されている私的使用や引用などの範囲内で行ってください。
著作権法に規定されている私的使用や引用などの範囲を超える利用を行う場合には、著作権者の許諾を得てください。ただし、著作権者から著作権等管理事業者（学術著作権協会、日本著作出版権管理システムなど）に権利委託されているコンテンツの利用手続きについては、各著作権等管理事業者に確認してください。
Chemotherapy under cachectic conditions and the possibility of cachexia-controlled chemotherapy

Y. Takahashi and K. Yasumoto

We studied the role of chemotherapy in cancer cachexia, which is well known to lower QOL as well as responsiveness to chemotherapy. In BALB/c mice we used two clones derived from the murine colon 26 adenocarcinoma cell line, clone 5, a non-cachexigenic tumor and clone 20, a cachexigenic tumor, in which IL-6 mRNA was selectively detected. While maximum tolerated dose (MTD) of CPM and CPT-11 showed significantly smaller tumor weight and higher survival than 1/2 MTD in both drug groups with clone 5, the results were reversed with clone 20 (Fig 1). The tumor weights with MTD of CPM or CPT-11 in combination with anti-IL-6 antibody treatment, which decreases serum IL-6 level and improves cachexia status, were significantly smaller than those in the MTD treatment-alone group with clone 20, but not with clone 5 (Fig 2).

From these results, we suggest that lower dose chemotherapy or cachexia-controlled chemotherapy such as some chemotherapeutic agents with neutralizing cachexia-related cytokine effects, elicits superior antitumor effects in cachectic individuals than conventional MTD chemotherapy.

Fig 1. Survival curves of CPT-11 therapy

Fig. 2. The effect of anti-IL-6 antibody